Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
Related Questions
Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?
Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
What is your approach to evaluation and management of GERD in a patient with IPF?
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
Have you adopted the use of low dose morphine for treatment of cough in patients with IPF?
How do you determine whether to add abatacept or rituximab to the treatment regimen in patients with mild RA-ILD on methotrexate?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
